<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149845">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02131688</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-HE14Ⅰ</org_study_id>
    <nct_id>NCT02131688</nct_id>
  </id_info>
  <brief_title>Phase I Study of Mitoxantrone Hydrochloride Liposome Injection</brief_title>
  <official_title>Phase I Dose Escalation Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Malignant Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose,the safety and
      effectiveness of Mitoxantrone Hydrochloride Liposome Injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial of the dose escalation method is from 18mg/m2 until the maximum tolerated dose and
      every 3 patient is a dose group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Mitoxantrone Hydrochloride Liposome Injection</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Malignant Lymphoma</condition>
  <arm_group>
    <arm_group_label>Mitoxantrone Hydrochloride Liposome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone Hydrochloride Liposome</intervention_name>
    <arm_group_label>Mitoxantrone Hydrochloride Liposome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must compliance with the requirements and restrictions listed in the consent
             form

          -  Patients with Pathology and / or cytologically proven malignant  lymphoma

          -  Patients must be 18-70 years old ,both male and female

          -  Failure of standard chemotherapy

          -  Patients have no better choice and may be benefit from the use of anthracyclines

          -  Patients with  Eastern Cooperative Oncology Group (ECOG)Performance Status of 0-2

          -  Objective tumor from the last chemotherapy, biological therapy or other experimental
             interval treatment least 4 weeks

          -  Expected survival time ≥ 3 months

          -  Patients agreed to take effective contraceptive measures during the trial

          -  Blood routine, liver and kidney function, cardiac function examination in accordance
             with the following requirements.

        Exclusion Criteria:

          -  Pregnancy and breast-feeding women

          -  Multiple sclerosis

          -  Patients that have histories of ischemic heart disease and heart
             congestive,arrhythmia that need to be a treatment and significant valvular disease

          -  Patients with heart disease induced by anthracycline

          -  Patients requiring other antineoplastic treatment

          -  Patients with temperature above 38 degrees or active infection that may effects in
             clinical tests

          -  Patients are allergic to anthracycline and liposomal drugs

          -  Patients are allergic to eggs,egg products,soybean and soybean products

          -  Patients with uncontrolled primary or metastatic brain tumorsMultiple sclerosis

          -  Patients that have histories of ischemic heart disease and heart
             congestive,arrhythmia that need to be a treatment and significant valvular disease

          -  Patients with heart disease induced by anthracycline

          -  Patients requiring other antineoplastic treatment

          -  Patients with temperature above 38 degrees or active infection that may effects in
             clinical tests

          -  Patients are allergic to anthracycline and liposomal drugs

          -  Patients are allergic to eggs,egg products,soybean and soybean products

          -  Patients with uncontrolled primary or metastatic brain tumors

          -  Total amount of Doxorubicin(or Pirarubicin)≥360mg/m2,Epirubicin ≥600mg/m2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital ,Chinese Academy of Mddical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Hospital ,Chinese Academy of Mddical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi, Ph.D</last_name>
      <phone>010-87788701</phone>
    </contact>
    <investigator>
      <last_name>Yuankai Shi, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianliang Yang, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>May 4, 2014</lastchanged_date>
  <firstreceived_date>May 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety;malignant lymphoma;</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
